U.S. corporations that thrived under two years of a Republican-controlled federal government will likely avoid any significant policy shifts after Democrats wrested back a slim majority in the House of Representatives.
More intense oversight, however, could bring both key Trump administration officials and large financial institutions into Congressional cross-hairs. A battle over government funding might undermine growth at defense contractors while scrutiny of rising drug costs could heighten already increasing pressure on the pharmaceutical industry.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.